Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
The present disclosure provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. Methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection.
1. A method of manufacturing a pharmaceutical composition, the method comprising:
receiving a stool from a human donor, wherein the stool comprises a collection of fecal bacteria;
testing the stool for pathogens;
separating the collection of fecal bacteria from rough particulate matter of the stool;
co-culturing the collection of fecal bacteria to produce a mixed bacterial culture comprising a first and second species of bacteria; and
formulating the pharmaceutical composition to include the first and second species of bacteria without isolating the first and second species of bacteria from the mixed bacterial culture prior to the formulating.
2. The method of claim 1 , wherein the separating comprises mixing the stool with a diluent to produce a homogenate, and filtering the homogenate.
3. The method of claim 1 , wherein the co-culturing comprises culturing the collection of fecal bacteria under anaerobic conditions.
4. The method of claim 1 , wherein the formulating comprises centrifuging the mixed bacterial culture.
5. The method of claim 1 , further comprising lyophilizing or spray drying the co-cultured bacteria to produce a powdered bacterial formulation.
6. The method of claim 5 , further comprising encapsulating the powdered bacterial formulation in a capsule.
7. The method of claim 6 , wherein the capsule is acid-resistant.
8. The method of claim 1 , further comprising supplementing the co-cultured bacteria with a bacterial isolate isolated from one or more human donors.
9. The method of claim 1 , wherein the collection of fecal bacteria is co-cultured in liquid media.
10. The method of claim 1 , wherein the co-cultured bacteria comprise species of Firmicutes, Bacteroides , or a combination thereof.
11. A method, comprising:
obtaining multiple species of fecal bacteria from a stool of a healthy human donor;
co-culturing the multiple species of fecal bacteria to produce a mixed bacterial culture comprising a first and second species of bacteria; and
formulating the co-cultured bacteria into a pharmaceutical composition without isolating the first and second species of bacteria from the mixed bacterial culture prior to the formulating.
12. The method of claim 11 , further comprising testing the stool or a portion thereof for pathogens prior to the co-culturing.
13. The method of claim 11 , further comprising lyophilizing or spray drying the co-cultured bacteria to produce a powdered bacterial formulation.
14. The method of claim 13 , further comprising encapsulating the powdered bacterial formulation in a capsule.
15. The method of claim 14 , wherein the capsule is acid-resistant.
16. The method of claim 11 , wherein the multiple species of fecal bacteria are co-cultured in liquid media.
17. The method of claim 11 , wherein the multiple species of bacteria belong to Firmicutes, Bacteroides , or a combination thereof.
18. The method of claim 11 , wherein the obtaining comprises mixing the stool with a diluent to produce a homogenate, and filtering the homogenate.
19. The method of claim 11 , wherein the co-culturing comprises culturing the multiple species of fecal bacteria under anaerobic conditions.
20. The method of claim 11 , further comprising supplementing the co-cultured bacteria with a bacterial isolate isolated from one or more human donors.